IFNA1 and Cirrhosis: In a randomized open phase II trial, treatment with elbasvir/grazoprevir (EBR/GZR) + sofosbuvir (SOF) for 12 weeks was highly effective for HCV patients treated either with or without peginterferon (PEG-IFN-α-2a) or for cirrhosis patients (134).